News and Announcements
Banxa’s recent listing on Toronto Stock Exchange (TSX) resulted in a 92% rally on Day 1
- Published January 05, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Banxa’s recent success in listing on the Toronto Stock Exchange (TSX Venture Exchange) making it the first Payment Service Provider (PSP) to be listed globally.
A PSP focused on providing clients safe, compliant access to the digital assets market, BANXA (TSX-V:BNXA – Banxa Holdings Inc.) pushes on its goal to onboard the general public to digital currency by building a fully compliant payment infrastructure that enables simple and secure conversion of fiat currency to digital currency.
Banxa’s recent listing on TSX resulted in a 92% rally on Day 1. The company continues to make waves in the industry as its flagship Business to Business (B2B) product reaches over 1.2 million users through its B2B customer network, while the company’s Business to Consumer (B2C) product portfolio encompasses a number of brands and has been in operation since 2014.
About Banxa
Banxa offers global and local payment methods like credit cards and retail store networks. With zero chargebacks and an easy to integrate API, exchanges, wallet providers and other industry players can offer their customers an easy and secure way to buy cryptocurrency.
Banxa takes care of all regulations, payment network integrations, operational overheads and fraud management. The company has been named one of ‘250 crypto companies to watch in 2020’ by cryptoweekly.co and one of ‘Australia’s fastest growing tech startups’ by Growthlist.
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
